<DOC>
	<DOCNO>NCT00657748</DOCNO>
	<brief_summary>The aim study determine whether oral supplementation lithium acetate may improve biological clinical prognosis patient Canavan Disease .</brief_summary>
	<brief_title>Lithium Acetate Canavan Disease</brief_title>
	<detailed_description>Canavan Disease autosomal recessive devastate demyelinate disease cause deficiency Aspartoacylase ( ASPA ) enzyme . There available treatment . ASPA deficiency lead : - accumulation high level N-acetylaspartate ( NAA ) , involve myelin degeneration epilepsy ; - deficient synthesis acetate oligodendrocyte , could impair CNS myelination.Lithium administration induces decrease NAA brain tremor rat ( animal model CD ) one patient ( JANSON , 2005 ) . On hand , administration acetate could improve myelination Canavan patients.For reason , propose combine treatment : Lithium Gluconate Glyceryl Triacetate ( GTA ) . Eighteen patient , age 1 15 year , receive oral GTA Lithium 4 month , treatment association 6 month . Patients sequentially evaluated end treatment 2 month thereafter : -tolerance therapy ( careful monitoring clinical biological parameter ) .- efficacy therapy clinical , biological radiological parameter . Particularly , evaluate use MRI-spectroscopy CSF sample decrease NAA increase acetate level brain .</detailed_description>
	<mesh_term>Deficiency Diseases</mesh_term>
	<mesh_term>Canavan Disease</mesh_term>
	<mesh_term>Lithium Carbonate</mesh_term>
	<mesh_term>Triacetin</mesh_term>
	<criteria>Clinical biochemical diagnosis Canavan disease Renal disease Thyroid disease Cardiac disease Impossibility perform brain MRI</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>15 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Leukodystrophy</keyword>
	<keyword>Canavan disease ,</keyword>
	<keyword>Aspartoacylase ,</keyword>
	<keyword>Lithium ,</keyword>
	<keyword>Glyceryl Triacetate</keyword>
</DOC>